Bausch + Lomb price target lowered to $17 from $18 at BofA

BofA lowered the firm’s price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps an Underperform rating on the shares. 2025 guidance, particularly EBITDA, likely disappointed investors even though B+L signaled lower expectations in early January, notes the analyst. The firm continues to believe the stock upside is limited until investors get more visibility into Bausch + Lomb’s separation from Bausch Health (BHC), the analyst added.